PrairieView Partners’s GSK GSK Stock Holding History

PrairieView Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,221	Closed	-$47K	–	384
2024 Q2	$47K	Buy	+1,221	New	+$51.4K	0.01%	210

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PrairieView Partners's GSK Position: Q3 2024 in Review

PrairieView Partners sold out of GSK (GSK) in Q3 2024, closing a stake of 1,221 shares — an estimated $47K sold.

PrairieView Partners first reported a position in GSK in Q2 2024 and held it in 1 quarter. The position peaked at $47K in Q2 2024. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

PrairieView Partners reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
PrairieView Partners sold 1,221 GSK shares in Q3 2024, an estimated $47K.
PrairieView Partners first reported a position in GSK in Q2 2024 and held it in 1 quarter.
PrairieView Partners's GSK position peaked at $47K in Q2 2024.
899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on PrairieView Partners's 13F filing for Q3 2024, filed 18 Oct 2024.